Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics NASDAQ: CAPR said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku.
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates
Capricor posted a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period.
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
Biotech Stock Up Over 400% After Late-Stage Breakthrough
Capricor Therapeutics Inc (NASDAQ:CAPR) is one of the best stocks on Wall Street today, up 263% to trade at $23.09, after the biotech company's cell therapy for a heart condition related to Duchenne's muscular dystrophy met the main goal of a late-stage study.
Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. ( CAPR ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Madison Wynne El-Saadi - B.
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2025 Earnings Conference August 13, 2025 4:30 PM ET Company Participants Anthony J. Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Catherine Clare Novack - JonesTrading Institutional Services, LLC, Research Division Edward Andrew Tenthoff - Piper Sandler & Co., Research Division Joseph Pantginis - H.C.
